I commend Florian A Wenzl and colleagues for extending the use of the Global Registry of Acute Coronary Events (GRACE) 3.0 ...

World TB Day, March 24, marks the day in 1882 that Robert Koch announced the discovery of Mycobacterium tuberculosis, responsible for the ancient disease now known as tuberculosis (TB). The disease ...

Clinical decision support (CDS) software plays an increasingly central role in health-care delivery, yet the ambiguous interpretations of regulations result in inconsistent application in clinical ...

Each year, an estimated 1·9 million children (aged 0–9 years) and adolescents (aged 10–19 years) develop tuberculosis disease ...

Tuberculosis remains a major global health threat, and symptom-based case detection fails to interrupt community transmission.1 Nearly half of tuberculosis cases are missed by current strategies, and ...

Preliminary results from the long-awaited COLOR III trial by Jurriaan Tuynman and colleagues, published in The Lancet Gastroenterology & Hepatology, show that transanal total mesorectal excision ...

Despite continuous improvements in sepsis outcomes over past decades, data suggest that overall prognosis has plateaued.1 Specifically, septic shock—a severe form of sepsis characterised by systemic ...

Urinary stone disease is common, associated with substantial morbidity, has a high recurrence rate, and affects quality of life.1,2 Consumption of large volumes of fluids is a foundational strategy ...

Clinical trial datasets are becoming increasingly complex, yet the format of their dissemination remains largely static.1 ...

In 2021, a global tuberculosis vaccine research and development roadmap proposed a series of actions to accelerate the development of new, effective, and affordable vaccines that are urgently needed ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...